• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by AIxCrypto Holdings Inc.

    4/17/26 4:24:47 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIXC alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on April 17, 2026.

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933

     

    AIxCrypto Holdings, Inc.
    (Exact name of registrant as specified in its charter)

     

    Delaware   26-3474527

    (State or other jurisdiction of
    incorporation or organization)

      (I.R.S. Employer
    Identification No.)

     

    AIxCrypto Holdings, Inc.

    1990 E. Grand Avenue
    El Segundo, CA 90245

    (760) 452-8111

    (Address of Principal Executive Offices) (Zip Code)

     

    2025 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Kevin A. Richardson II

    Jiawei Wang

    Co-Chief Executive Officers

    AIxCrypto Holdings, Inc.

    1990 E. Grand Avenue

    El Segundo, CA 90245

    (760) 452-8111

     

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Henry Yin, Esq.

    Loeb & Loeb LLP

    2206-19 Jardine House

    1 Connaught Place

    Central, Hong Kong SAR

    +852-3923-1111

    Hermione M. Krumm, Esq.

    Loeb & Loeb LLP

    345 Park Avenue

    New York, NY 10154

    (212) 407-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by AIxCrypto Holdings, Inc. (the “Registrant”) to register an aggregate of 1,047,865 shares of the Registrant’s common stock, par value $0.001 per share, reserved and available for issuance pursuant to the Registrant’s 2025 Equity Incentive Plan (the “Plan”).

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    ITEM 1. PLAN INFORMATION*

     

    ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION*

     

    * Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the Note to Part I of Form S-8. The documents containing information specified in this Part I will be separately provided to the participants in the Plan covered by this Registration Statement, as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.  

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed with the Securities and Exchange Commission (the “Commission”) by the Registrant are incorporated herein by reference:

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026;

     

      (b) the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 6, 2026 February 2, 2026, February 17, 2026, February 27, 2026 and April 16, 2026; and

     

      (c) the description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on June 12, 2015, including any amendments or reports filed for the purpose of updating that description.

     

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than those furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or other information “furnished” to the Commission) prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the time of filing of such documents.

     

    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Subject to the foregoing, all information in this Registration Statement is so qualified in its entirety by the information appearing in the documents incorporated herein by reference.

     

    ITEM 4. DESCRIPTION OF SECURITIES

     

    Not applicable.

     

    ITEM 5. INTEREST OF NAMED EXPERTS AND COUNSEL

     

    Not applicable.

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Section 145 of the General Corporation Law of the State of Delaware (“DGCL”) provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, were or are a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation’s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred.

     

     

     

     

    Section 145 of the DGCL further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of their status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145 of the DGCL.

     

    Article VIII of the Amended and Restated Certificate of Incorporation of the Registrant (the “Charter”) provides, in part, that a director of the Company shall not be personally liable to the Company or its stockholders for monetary damages for a breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involved intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit. Article IX of the Charter and Article 6 of the Amended and Restated Bylaws of the Company (the “Bylaws”) generally provide for indemnification of directors and officers of the Company to the fullest extent permitted by the DGCL.

     

    The foregoing is only a general summary of certain aspects of the DGCL and the Company’s organizational documents dealing with indemnification of directors and officers and does not purport to be complete summary of the same. As a result, this Item 6 is qualified in its entirety by reference to the applicable provisions of the DGCL and of the Charter and Bylaws.

     

    The Company has obtained directors’ and officers’ liability insurance, which insures against liabilities that its directors or officers may incur in such capacities.  

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

     

    Not applicable.

     

    ITEM 8. EXHIBITS

     

    See the attached Exhibit Index.

     

    ITEM 9. UNDERTAKINGS

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

     

     

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by any such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether or not such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, on April 17, 2026.

     

      AIxCrypto Holdings, Inc.
         
      By: /s/ Kevin A. Richardson II
      Name: Kevin A. Richardson II
      Title: Chairman of the Board, Co-Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kevin A. Richardson II and Jiawei Wang, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-1, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Kevin A. Richardson II   Co-Chief Executive Officer   April 17, 2026
    Kevin A. Richardson II   (Principal Executive Officer)    
             
    /s/ Jiawei Wang   Co-Chief Executive Officer   April 17, 2026
    Jiawei Wang        
             
    /s/ Campbell Becher   President   April 17, 2026
    Campbell Becher        
             
    /s/ Koti Meka   Chief Financial Officer and Executive Director   April 17, 2026
    Koti Meka   (Principal Financial Officer and Accounting Officer)    
             
    /s/ Kevin Chen   Director   April 17, 2026
    Kevin Chen        
             
    /s/ Jie Sheng   Chairman of the Board and Director   April 17, 2026
    Jie Sheng        
             
    /s/ Chad Chen   Director   April 17, 2026
    Chad Chen        

     

     

     

     

    Exhibit
    Number
      Description
    4.1   Amended and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on July 1, 2015 (File No. 001-37428))
    4.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on September 15, 2017 (File No. 001-37428))
    4.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on March 22, 2018 (File No. 001-37428))
    4.4   Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 29, 2020 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on May 29, 2020 (File No. 001-37428))
    4.5   Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 (incorporated by reference to Exhibit 3.2 of our current report on Form 8-K, filed with the SEC on May 29, 2020 (File No. 001-37428))
    4.6   Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020 (incorporated by reference to Exhibit 3.3 of our current report on Form 8-K, filed with the SEC on May 29, 2020 (File No. 001-37428))
    4.7   Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 (incorporated by reference to Exhibit 3.4 of our current report on Form 8-K, filed with the SEC on May 29, 2020 (File No. 001-37428))
    4.8   Amended and Restated Bylaws of the Company, as of August 10, 2021 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on August 13, 2021 (File No. 001-37428))
    4.9   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on November 21, 2022 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on November 22, 2022 (File No. 001-37428))
    4.10   Certificate of Designation of Series A2 Preferred Stock filed with the Secretary of State of Delaware on November 18, 2024 (incorporated by reference to Exhibit 3.2 of our current report on Form 8-K, filed with the SEC on November 21, 2024 (File No. 001-37428))
    4.11   Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred, as filed with the Secretary of State of the State of Delaware on July 28, 2025 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on July 28, 2025 (File No. 001-37428))
    4.12   Certification of Stock Designation of Rights and Preferences of Series B Convertible Preferred Stock as filed with the Secretary of State of Delaware on September 29, 2025 (incorporated by reference to Exhibit 4.1 of our current report on Form 8-K, filed with the SEC on September 25, 2025 (File No. 001-37428))
    4.13   Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on November 14, 2025 (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K, filed with the SEC on November 17, 2025 (File No. 001-37428))
    5.1*   Opinion of Loeb & Loeb LLP
    10.1*   2025 Equity Incentive Plan
    23.1*   Consent of Loeb & Loeb LLP (contained in Exhibit 5.1)
    23.2*   Consent of HTL International, LLC, Independent Registered Public Accounting Firm
    23.3*   Consent of WithumSmith+Brown, PC, Independent Registered Public Accounting Firm
    24.1*   Power of Attorney (included in the signature page)
    107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

    Get the next $AIXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets with Blockchain Infrastructure

    Key Points:An amendment to the securities purchase agreement dated January 30, 2026 (the "SPA") removed the true-up share mechanism and replaced it with a milestone-linked warrant capped at one million shares at $1.50 per shareThe Amended and Restated SPA increases the total investment amount to $12 millionThe warrant has a term expiring in April 2030 and is exercisable only upon delivery of 500 FX Super One vehiclesThe AIXC ecosystem is exploring the potential for a portion of the acquired FFAI shares to serve as underlying assets for future equity tokenization initiatives facilitated by ecosystem participants, subject to applicable regulatory and third-party approvalsLOS ANGELES, April 17,

    4/17/26 5:32:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    Faraday Future Amends $10 Million Equity Investment Agreement to $12 Million, Eliminating Anti-Dilution Provision to Strengthen Stockholder Protections

    Increase the Subscription Amount from $10 million to $12 million, $500,000 of which was used to purchase shares of Common Stock and $11.5 million of which was used to purchase shares of the Company's newly designated Series C preferred stock, which is convertible into the Company' Common Stock. AIXC and the designated third-party will use the US$500,000 of common stock to explore the real-world asset (RWA) business. Replace the true-up provision by issuance of a warrant. On the Closing Date, the Company issued to the Investor a warrant to purchase up to 1,000,000 shares of Common Stock at an exercise price of $1.50 per share with a term of 4 years, exercisable only after the delivery

    4/15/26 6:30:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: RWA Exploration, Ecosystem Development, and External Engagement

    LOS ANGELES, April 14, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today shared a weekly business update highlighting progress across its RWA initiatives, ecosystem development, and external engagement. Advancing RWA Infrastructure ExplorationDuring the week, AIxC continued to advance its real-world asset (RWA) initiatives across multiple workstreams, with a focus on exploring infrastructure that enables the on-chain representation of traditional financial assets.The Company has initiated early-stage engagement with a

    4/14/26 1:28:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    SEC Filings

    View All

    SEC Form S-8 filed by AIxCrypto Holdings Inc.

    S-8 - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    4/17/26 4:24:47 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    4/16/26 4:05:34 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by AIxCrypto Holdings Inc.

    10-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/30/26 6:21:26 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Financials

    Live finance-specific insights

    View All

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: [email protected]. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials